Shots:
Proteros to receive research funding, ~$75M in success-based research, development, and commercial milestones along with royalties
Based on a June 2021 agreement, the new collaboration will combine Proteros’ expertise in the identification & characterization of inhibitors with binding mechanisms for drug targets with AstraZeneca’s leadership to discover novel inhibitors for cancer patients
The Proteros platform will use biochemical, biophysical & cellular assays to ensure high selectivity to a specific target variant within & across multiple protein families along with a rapid structural determination of drug-target interactions using X-ray crystallography & cryo-electron Microscopy technologies
Ref: Businesswire | Image: Proteros
